


Identifying Patients Who Can Benefit From iDose TR

iDose[®]TR[®]
(travoprost intracameral implant) 75 mcg

iDose TR is a long duration intracameral procedural pharmaceutical that delivers prostaglandin analog therapy for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).¹

May be utilized as a standalone procedure or in combination with cataract surgery.

iDose TR Extends Across the Spectrum of Glaucoma




Potential Patients Who May Benefit from iDose TR:

- Non-compliant/non-adherent to topical glaucoma medication(s)
- Intolerant or allergic to topical glaucoma medication(s)
- Experienced side effects on topical glaucoma medications that have affected quality of life
- Uncontrolled on topical glaucoma medication(s)
- Underlying co-morbidities (eg, ocular surface disease)
- Underwent prior intervention (eg, SLT, etc.) and remain in need of therapy

Real-World Adverse Events When Using Topical Therapy



Treatment Non-Adherence



Hyperemia²



Periorbital Fat Atrophy

If you have a patient who struggles with any of the above challenges, consider talking to them about the benefits of iDose TR.

EXAMPLE PATIENT PROFILES

iDose TR can help a variety of patients keep glaucoma under control. Considerations include medical history, treatment experience, and adherence with current medication.



EXAMPLE PATIENT 1
Age 75

CURRENT TREATMENT

Prescribed PGA six months ago; struggled with compliance and discontinued due to side effects



EXAMPLE PATIENT 2
Age 65

CURRENT TREATMENT

On one topical medication and IOP is uncontrolled; has developed cataracts



EXAMPLE PATIENT 3
Age 70

CURRENT TREATMENT

Had SLT 12 months ago; on two topical medications and IOP is not at target

Consider these types of patients within your practice who may be potential candidates for the iDose TR treatment. **Visit our website at iDoseTRhcp.com**

1. iDose TR (travoprost intracameral implant) 75 mcg Prescribing Information. Glaukos Corporation. 2023.
2. Imperial College NHS Trust, UK

INDICATIONS AND USAGE

iDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT).

IMPORTANT SAFETY INFORMATION

DOSAGE AND ADMINISTRATION

For ophthalmic intracameral administration. The intracameral administration should be carried out under standard aseptic conditions.

CONTRAINDICATIONS

iDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch's Dystrophy, corneal guttatae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet's Stripping Automated Endothelial Keratoplasty [DSAEK]), patients with hypersensitivity to travoprost or to any other components of the product.

WARNINGS AND PRECAUTIONS

iDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to confirm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent.

ADVERSE REACTIONS

In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperaemia, and reduced visual acuity.

Please see full [Prescribing Information](#).

You are encouraged to report all side effects to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also call Glaukos at 1-888-404-1644.



View full prescribing
information at
iDoseTRhcp.com

GLAUKOS[®]